NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) today announced operational and financial results for the second quarter ended September 30, 2010. The Company confirmed that its commercial preparations for the launch of vilazodone, if approved for the treatment of depression, are accelerating as the decision date assigned under the Prescription Drug User Fee Act (PDUFA) of January 22, 2011 rapidly approaches. Phase III development of Stedivaze, the Company’s coronary vasodilator for use in nuclear-SPECT myocardial perfusion imaging, is also advancing with plans to initiate a second Phase III trial in early calendar year 2011.
